Search
Search Results
-
Multiple Sclerosis Management: Current Clinical Approaches to Disease-Modifying Therapy
Purpose of ReviewThe treatment landscape for multiple sclerosis has evolved and expanded significantly over the past 30 years, with now over 20...
-
The potential value of disease-modifying therapy in patients with spinocerebellar ataxia type 1: an early health economic modeling study
ObjectiveThere currently is no disease-modifying therapy for spinocerebellar ataxia type 1 (SCA1). Genetic interventions, such as RNA-based...
-
Combination Therapy for Psoriasis with Methotrexate and Other Oral Disease-Modifying Antirheumatic Drugs: A Systematic Review
IntroductionAlthough the introduction of biologics and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) has reshaped the treatment...
-
Subacute cutaneous lupus erythematosus as a rare complication of disease-modifying therapy administration in multiple sclerosis: case report
BackgroundTeriflunomide, the active metabolite of leflunomide, is a disease-modifying therapy drug used for the treatment of multiple sclerosis (MS),...
-
Performance of Plasma Biomarkers Combined with Structural MRI to Identify Candidate Participants for Alzheimer’s Disease-Modifying Therapy
BackgroundRecently, two monoclonal antibodies that lower amyloid plaques have shown promising results for the treatment of Mild Cognitive Impairment...
-
What is the association of depression with clinical response to therapy in patients with psoriatic arthritis treated with biologic disease-modifying antirheumatic drugs?
IntroductionPsoriatic arthritis (PsA) is a chronic, progressive inflammatory joint disease that is associated with higher prevalence of depression....
-
Do Disease-Modifying Anti-rheumatic Drugs and Exercise Therapy Have a Combined Effect on Disease Activity in Patients with RA? A Sco** Review
Purpose of ReviewIn addition to disease-modifying anti-rheumatic drug (DMARD) treatment, exercise is increasingly promoted in patients with...
-
Clinical Management in Alzheimer’s Disease in the Era of Disease-Modifying Therapies
Purpose of reviewDiscuss emerging anti-amyloid disease-modifying therapies for Alzheimer’s disease (AD) and outline how these therapies will change...
-
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic
BackgroundThe COVID-19 pandemic raised concern amongst clinicians that disease-modifying therapies (DMT), particularly anti-CD20 monoclonal...
-
Clinicians’ Perspectives on How Disease Modifying Drugs for Alzheimer’s Disease Impact Specialty Care
Clinicians specialized in the diagnosis and management of persons living with early-stage Alzheimer’s disease need to enable access, for those...
-
Long-Term Outcomes of Disease Modifying Therapies in Gaucher Disease
ObjectivesTo study clinical response to treatment with enzyme replacement therapy (ERT) and substrate reduction therapy (SRT) in a cohort of Gaucher...
-
Novel Blood-Based Biomarkers and Disease Modifying Therapies for Alzheimer’s Disease. Are We Ready for the New Era?
Recent positive trials for novel disease modifying therapies of anti-amyloid monoclonal antibodies represent a paradigm shift in the prevention and...
-
Effects of confounding and effect-modifying lifestyle, environmental and medical factors on risk of radiation-associated cardiovascular disease
BackgroundCardiovascular disease (CVD) is the leading cause of death worldwide. It has been known for some considerable time that radiation is...
-
Disease-Modifying Medications in Patients with Rheumatoid Arthritis in the USA: Trends from 2016 to 2021
BackgroundDisease-modifying anti-rheumatic drugs (DMARDs), since their introduction in 1990, have revolutionized the management of rheumatoid...
-
Factors determining resistance to conventional disease-modifying anti-rheumatic drug treatment in oligoarticular juvenile idiopathic arthritis
ObjectiveOur study was designed to investigate the reasons for starting the conventional disease-modifying anti-rheumatic drugs (DMARDs) and the...
-
De-escalation of Disease-Modifying Therapy for People with Multiple Sclerosis Due to Safety Considerations: Characterizing 1-Year Outcomes in 25 People Who Switched from Ocrelizumab to Diroximel Fumarate
IntroductionSwitching disease-modifying therapy (DMT) may be considered for relapsing–remitting multiple sclerosis (RRMS) if a patient’s current...
-
Intracerebral haemorrhage in multiple sclerosis: assessing the impact of disease-modifying medications
Multiple Sclerosis (MS) is a complex autoimmune disorder that significantly impacts the central nervous system, leading to a range of complications....
-
Disease-modifying therapies and features linked to treatment response in type 1 diabetes prevention: a systematic review
BackgroundType 1 diabetes (T1D) results from immune-mediated destruction of insulin-producing beta cells. Prevention efforts have focused on immune...
-
Challenges and Opportunities in Titrating Disease-Modifying Therapies in Heart Failure with Reduced Ejection Fraction and Chronic Kidney Disease
Purpose of ReviewChronic kidney disease (CKD) is highly prevalent in patients with heart failure and reduced ejection fraction (HFrEF), representing...
-
Neuromodulation as a Potential Disease-Modifying Therapy for Osteoarthritis
Purpose of ReviewThe following review discusses the therapeutic potential of targeting the autonomic nervous system (ANS) for osteoarthritis (OA)...
